Herpes Simplex Virus Treatment: A Global Strategic Business Report
San Jose, California (PRWEB) April 23, 2012
Follow us on LinkedIn – Genital herpes is one of the most common sexually transmitted diseases in the US. The prevalence of genital herpes is estimated at 63 million in the US alone, with about 500,000 to 1,000,000 new cases being diagnosed every year. According to the Centers for Disease Control and Prevention, the rate of infection of genital herpes has increased by about 30% between the late 1970s and the early 1990s. However, since more than 80% of people with genital herpes do not have an idea that they are infected, resulting in low diagnosis rate, there exists significant growth potential for Herpes Simplex Virus (HSV) treatment drugs. In addition, the lack of availability of drugs for the complete curing of HSV also bodes well for the development of new drugs. The HSV market presently includes various anti-viral therapies that alleviate painful symptoms of the infection. However, these drugs are known to cause drug related toxicity as a result of their interference with the natural metabolism of the human body. The availability of safer drugs, therefore, is a primary requirement for the therapeutics market. In addition, with the virus subsequently developing resistance against the existing batch of anti-virals, the need for innovative therapies for the treatment of herpes simplex infection, and the search for novel antiviral drugs continues. This presents a huge potential for the growth of herpes simplex therapeutics market in future.
The US represents the largest regional market for Herpes Simplex Virus (HSV) treatment worldwide, as stated by the new market research report on Herpes Simplex Virus Treatment. However, growth in the market is expected to emanate mainly from the developing markets and other regions. Rest of World is projected to post a compounded annual growth rate of close to 7% during the analysis period 2009-2107.
Herpes therapeutics market is considerably genericized. One of the key factors hampering prospects for new drugs is the generic incursion in the market, which led to the entry of several generic variants and reduced prices of the drugs in the market. However, the market is expected to post strong growth, owing to continuing rise in the incidence of herpes simplex virus infection. A strong pipeline of vaccines for the prevention and treatment of HSV2 constitutes another growth driver. Although the market presently awaits the commercial launch of the first such HSV vaccine, there are about eleven vaccines, including prophylactic, therapeutic and a combination of both, currently under development at various stages of development. Besides, another promising area in the HSV treatment includes the emergence of Nanoviricides drugs, which are expected to provide increased opportunities owing to their distinct mechanism of action in comparison to the existing drugs.
Major players profiled in the report include Agenus Inc., AiCuris GmbH & Co.KG, Astellas Pharma Inc., Clinigen Group, Cytogenix Inc., Genocea Biosciences, GlaxoSmithKline Plc., Lumavita AG, NanoBio Corporation, NanoViricides Inc., Novartis International AG, Sanofi, Starpharma Holdings Limited, Vical, Genocea Biosciences, among others.
The research report titled “Herpes Simplex Virus Treatment: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of the Herpes Simplex Virus treatment, current market trends, key growth drivers, the available treatment, overview of major drugs, insight into current leading and pipeline drugs, recent product approvals, recent industry activity, and profiles of major/niche global as well as regional market participants. The report provides annual sales estimates and projections for Herpes Simplex Virus treatment for the years 2009 through 2017 for the following geographic markets - US, Europe, and Rest of World.
For more details about this comprehensive market research report, please visit –
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.
Global Industry Analysts, Inc.
Web Site: http://www.StrategyR.com/